Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsShortsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Linda Wenger, LUNGevity Foundation

Advertisement

Articles by Linda Wenger, LUNGevity Foundation

LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients

ByLinda Wenger, LUNGevity Foundation
June 20th 2018

Key recommendations from LUNGevity's Expanded Eligibility working group were published in the Journal of Thoracic Oncology.

Advertisement

Latest Updated Articles

  • LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients
    LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients

    June 20th 2018



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Managing Rash and Stomatitis With Daraxonrasib in Pancreatic Cancer

2

FDA Approves Oral Nilotinib Tablets for Ph+ CML

3

Nursing Guide to Managing Lorlatinib in ALK+ NSCLC: 7-Year CROWN Insights

4

GLP-1 RAs Linked to Lower HR+ Breast Cancer Risk and Improved Survival

5

Frailty Score Shows Link to Toxicity, Mortality Risk With Novel Cancer Therapies

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us